Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The patient must have signed and dated an IRB-approved consent form that conforms to federal and institutional guidelines.~* Female~* 18 years or older~* ECOG performance status of 0 or 1~* Eligible tumors must meet one of the following criteria:~  * Operable (T1c, T2-3, N0-1, M0)~ * Locally advanced (T2-3, N2-3, M0 or T4a-c, any N, M0)~ * Inflammatory breast cancer (T4d, any N, M0)~* Staging evaluation:~  * History and physical exam, cbc, chemistry profile~ * CT Chest/Abdomen/Pelvis and a bone scan or PET/CT as needed~* Diagnosis of invasive adenocarcinoma made by core needle biopsy~* Breast cancer determined to be:~* Confirmed HER2-positive : (ASCO CAP guidelines, 10/7/2013)~  * IHC 3+ based on circumferential membrane staining that is complete, intense~ * ISH positive based on:~ * Single probe average HER2 copy number ≥ 6 signals/cell~ * Dual probe HER2/CEP 17 ratio ≥ 2.0 with an average HER2 copy number ≥ 4.0 signals/cell~ * Dual probe HER2/CEP 17 ratio ≥ 2.0, with an average HER2 copy number of \< 4.0 signals/cell~ * Dual probe HER2/CEP 17 ratio \< 2.0 with the average HER2 copy number of ≥ 6.0 signals/cell~* any ER or PR receptor status~* LVEF assessment by echocardiogram within 30 days of initiation; EF of ≥ 55% considered normal.~* Normal troponin I level at baseline~* Blood counts must meet the following criteria:~  * ANC greater than or equal to 1500/mm3~ * Platelet count greater than or equal to 100,000/mm3~ * Hemoglobin greater than or equal to 10 g/dL~* Serum creatinine less than or equal 2.5 mg/100ml~* Adequate hepatic function by these criteria: total bilirubin must be less than or equal to 1.5 x the ULN for the lab unless the patient has a bilirubin elevation great than the ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab; and AST must be less than or equal to 1.5 x ULN for the lab. Both alkaline phosphatase and AST may not both be greater than the ULN.~* Patients with AST or alkaline phosphatase \> ULN are eligible for inclusion in the study if liver imaging (CT, MRI, PET-CT or PET scan) performed within 90 days prior to randomization does not demonstrate metastatic disease and the requirements are met as above~* Patients with alkaline phosphatase that is \> ULN but less than or equal to 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 90 days prior to randomization does not demonstrate metastatic disease.~Exclusion Criteria:~Patients with a history of decompensated congestive heart failure or an EF \< 55% will be excluded~• Cardiac disease that would preclude the use of the drugs included in the above regimens. This includes but is not confined to:~* Active cardiac disease:~* angina pectoris requiring the use of anti-anginal medication;~* ventricular arrhythmias except for benign premature ventricular contractions controlled by medication;~* conduction abnormality requiring a pacemaker;~* supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; and~* clinically significant valvular disease~* symptomatic pericarditis~* pulmonary hypertension~* History of cardiac disease:~* myocardial infarction;~* congestive heart failure; or~* cardiomyopathy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ddACTHP (Type: ACTIVE_COMPARATOR): Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Pegfilgrastim 6mg SC, day 2 of AC~Cycled every 14 days for 4 cycles, followed by, Paclitaxel 80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15 Trastuzumab 8 mg/kg IV day 1, followed by 6mg/kg Pertuzumab loading dose 840 mg IV followed by 420 mg IV every 3 weeks~Cycled every 21 days for 4 cycles, followed by, Trastuzumab 6mg/kg every 21 days to complete 1 year
- TCHP (Type: ACTIVE_COMPARATOR): TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Pegfilgrastim ) institutional practice is to titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval